Baxter International Inc
BAX- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000010456
No open-market purchases or sales by Baxter International Inc insiders were filed in the last 90 days; 689 institutions reported holding it in 13F filings for Q2 2026, worth $11.9B in total; Greenhaven Associates is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Baxter International Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Baxter International Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Teaff James | President, CCS | 30,370 | Sep 3, 2026 | 2 |
| Hider Andrew P. | President and CEO | 518,447 | Sep 3, 2026 | 2 |
| Foster Julie | President, Front Line Care | 29,164 | Sep 3, 2026 | 1 |
| Zielinski Anita A | SVP, Interim CFO, CAO & Cntrlr | 59,714 | Jun 3, 2026 | 3 |
| Wallace Steven P. | President, Adv. Surgery | 70,128 | Jun 3, 2026 | 1 |
| McDonnell Michael R | Director | 14,647 | May 7, 2026 | 2 |
| Morrison Patricia | Director | 42,386 | May 7, 2026 | 1 |
| Craig Jeffrey A | Director | 23,662 | May 7, 2026 | 1 |
| Schlichting Nancy M | Director | 34,994 | May 7, 2026 | 1 |
| Wendell Amy McBride | Director | 44,235 | May 7, 2026 | 1 |
| Shafer David Brent | Director, Other: Chair of the Board | 72,804 | May 7, 2026 | 1 |
| Wilkes David S. | Director | 37,076 | May 7, 2026 | 1 |
| Ampofo William A. II | Director | 30,375 | May 7, 2026 | 1 |
| Grade Joel T. | EVP and CFO | 271,674 | Mar 10, 2026 | 4 |
| Rosenbloom David S. | EVP and General Counsel | 138,216 | Mar 10, 2026 | 3 |
| Rasul Reaz | EVP,Group Pres,Healthcare | 125,557 | Mar 10, 2026 | 3 |
| Soriano Maria Cecilia | Group Pres., ITT & Pharma. | 75,045 | Mar 10, 2026 | 3 |
| Carlisle Cynthia | Executive Vice President, CHRO | 29,677 | Mar 3, 2026 | 1 |
| Mason Jeanne K | EVP, Chief HR Officer | 199,853 | Dec 16, 2025 | 1 |
| Borzi James W | EVP,Chief Supply Chain Officer | 71,948 | Sep 4, 2025 | 0 |
| Sonig Alok | EVP,Group President,Pharma | 128,219 | Sep 4, 2025 | 0 |
| Rusckowski Stephen H | Director | 16,499 | May 8, 2025 | 0 |
| Oesterle Stephen N. | Director | 35,847 | May 8, 2025 | 0 |
| Smith Cathy R | Director | 30,345 | May 8, 2025 | 0 |
| Knight Heather | EVP, Chief Operating Officer | 177,362 | Mar 10, 2025 | 0 |
| Toth Christopher A. | EVP, Group Pres, Kidney Care | 105,186 | Feb 4, 2025 | 0 |
| Almeida Jose E | Chairman, CEO, President | 243,589 | Dec 17, 2024 | 0 |
| Wilver Peter M | Director | 13,267 | May 9, 2024 | 0 |
| Stevens Brian | SVP, CAO & Controller | 67,538 | Mar 8, 2024 | 0 |
| Mahoney Michael F | Director | 9,692 | May 4, 2023 | 0 |
| Stroucken Albert P L | Director | 36,835 | Mar 22, 2023 | 0 |
| Saccaro James | EVP, Chief Financial Officer | 177,899 | Mar 6, 2023 | 0 |
| Franzi Cristiano | SVP, President, EMEA | 102,145 | Mar 6, 2023 | 0 |
| Kunzler Jacqueline | SVP, Chief Quality Officer | 22,625 | Mar 6, 2023 | 0 |
| Flynn Steven | SVP, President, APAC | 31,080 | Mar 3, 2023 | 0 |
| Hellman Peter S | Director | 30,335 | May 5, 2022 | 0 |
| Chen Thomas F | Director | 15,740 | May 5, 2022 | 0 |
| Forsyth John D | Director | 27,029 | Apr 5, 2022 | 0 |
| Martin Sean | SVP and General Counsel | 52,632 | Mar 4, 2022 | 0 |
| Accogli Giuseppe | EVP, Chief Operating Officer | 76,495 | Mar 4, 2022 | 0 |
| Frye Andrew | SVP, President, APAC | 22,002 | Mar 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2024 (view filing) | Mar 1 | 4 days | Mason Jeanne KEVP, Chief HR Officer | SSaleCommon Stock, $1 par value | −64.5K | $40.61 | −$2.62M | −31.2%142.3K after | 10b5-1 |
| Mar 22, 2023 (view filing) | Mar 20 | 2 days | Stroucken Albert P LDirector | SSaleCommon Stock, $1 par value | −3.93K | $37.52 | −$147.5K | −9.6%36.8K after | |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Kunzler JacquelineSVP, Chief Quality Officer | SSaleCommon Stock, $1 par value | −3.81K | $40.50 | −$154.4K | −18.6%16.7K after | |
| Jan 19, 2023 (view filing) | Jan 17 | 2 days | Mason Jeanne KSVP, Human Resources | SSaleCommon Stock, $1 par value | −59.5K | $44.70 | −$2.66M | −32.0%126.2K after | |
| Apr 7, 2022 (view filing) | Apr 5 | 2 days | Stroucken Albert P LDirector | SSaleCommon Stock, $1 par value | −4.02K | $76.02 | −$305.6K | −10.5%34.1K after | 2 lots |
| Apr 7, 2022 (view filing) | Apr 5 | 2 days | Hellman Peter SDirector | SSaleCommon Stock, $1 par value | −4.02K | $76.02 | −$305.6K | −12.7%27.6K after | 2 lots |
| Apr 5, 2022 (view filing) | Apr 1 | 4 days | Forsyth John DDirector | SSaleCommon Stock, $1 par value | −1.00K | $77.68 | −$78.1K | −3.6%27.0K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Forsyth John DDirector | SSaleCommon Stock, $1 par value | −1.00K | $84.82 | −$85.2K | −3.6%27.0K after | |
| Mar 1, 2022 (view filing) | Feb 28 | 1 day | Stevens BrianSVP, CAO and Controller | SSaleCommon Stock, $1 par value | −2.50K | $85.50 | −$213.8K | −15.1%14.0K after | 2 lots |
| Feb 16, 2022 (view filing) | Feb 14 | 2 days | Mason Jeanne KSVP, Human Resources | SSaleCommon Stock, $1 par value | −54.1K | $85.02 | −$4.60M | −30.9%121.1K after | 2 lots |
| Feb 3, 2022 (view filing) | Feb 2 | 1 day | Chen Thomas FDirector | SSaleCommon Stock, $1 par value | −1.68K | $84.53 | −$142.0K | −11.5%13.0K after | |
| Feb 3, 2022 (view filing) | Feb 1 | 2 days | Forsyth John DDirector | SSaleCommon Stock, $1 par value | −1.00K | $85.59 | −$86.0K | −3.6%27.0K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Martin SeanSVP and General Counsel | SSaleCommon Stock, $1 par value | −21.4K | $79.57 | −$1.71M | −33.7%42.3K after | 2 lots |
| Aug 4, 2021 (view filing) | Aug 2 | 2 days | Martin SeanSVP and General Counsel | SSaleCommon Stock, $1 par value | −19.8K | $77.26 | −$1.53M | −31.9%42.2K after |